Class information for:
Level 1: SELEGILINE//RASAGILINE//DEPRENYL

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
7937 1311 41.5 68%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
11 4 NEUROSCIENCES//CLINICAL NEUROLOGY//NEUROL 1112395
124 3       PARKINSONS DISEASE//MOVEMENT DISORDERS//DEEP BRAIN STIMULATION 67777
332 2             PARKINSONS DISEASE//ALPHA SYNUCLEIN//PARKIN 18089
7937 1                   SELEGILINE//RASAGILINE//DEPRENYL 1311

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 SELEGILINE authKW 2497100 15% 55% 194
2 RASAGILINE authKW 2374428 11% 72% 141
3 DEPRENYL authKW 1877755 11% 55% 147
4 L DEPRENYL authKW 1022456 5% 73% 60
5 SAFINAMIDE authKW 331306 2% 68% 21
6 EVE TOPF EXCELLENCE NEURODEGENERAT DIS address 315889 2% 59% 23
7 R P ORT FAMILY address 210172 1% 48% 19
8 EVE TOPF address 209604 1% 75% 12
9 DEPRENYL SELEGILINE authKW 179149 1% 77% 10
10 DESMETHYLSELEGILINE authKW 165616 1% 89% 8

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Clinical Neurology 5341 28% 0% 373
2 Neurosciences 4995 37% 0% 481
3 Pharmacology & Pharmacy 4665 36% 0% 468
4 Geriatrics & Gerontology 848 5% 0% 60
5 Psychiatry 181 5% 0% 70
6 Medicine, Research & Experimental 113 5% 0% 61
7 Behavioral Sciences 59 2% 0% 26
8 Chemistry, Medicinal 57 3% 0% 36
9 Toxicology 39 2% 0% 32
10 Chemistry, Analytical 23 3% 0% 45

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 EVE TOPF EXCELLENCE NEURODEGENERAT DIS 315889 2% 59% 23
2 R P ORT FAMILY 210172 1% 48% 19
3 EVE TOPF 209604 1% 75% 12
4 EVE TOPF USA PARKINSON FDN EXCELLENCE 134743 1% 64% 9
5 EVE TOPF NEURODEGENERAT DIS 110894 1% 48% 10
6 EVE TOPF NPF 93160 0% 100% 4
7 R P ORT FAMILY MED HAIFA 93160 0% 100% 4
8 NPF 83839 0% 60% 6
9 NPF NEURODEGENERAT DIS 74526 0% 80% 4
10 R P ORT FAMILY MED 68110 1% 21% 14

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT 40238 3% 5% 37
2 JOURNAL OF NEURAL TRANSMISSION 17227 4% 1% 55
3 CLINICAL NEUROPHARMACOLOGY 9920 2% 1% 32
4 JOURNAL OF NEURAL TRANSMISSION-PARKINSONS DISEASE AND DEMENTIA SECTION 6639 1% 4% 8
5 JOURNAL OF NEURAL TRANSMISSION-GENERAL SECTION 4473 1% 2% 11
6 ACTA NEUROLOGICA SCANDINAVICA 4395 3% 1% 34
7 MOVEMENT DISORDERS 3843 3% 1% 33
8 POLISH JOURNAL OF PHARMACOLOGY AND PHARMACY 2982 1% 1% 10
9 NEUROLOGY 2162 3% 0% 45
10 BIBLIOTHECA PSYCHIATRICA 2021 0% 4% 2

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 SELEGILINE 2497100 15% 55% 194 Search SELEGILINE Search SELEGILINE
2 RASAGILINE 2374428 11% 72% 141 Search RASAGILINE Search RASAGILINE
3 DEPRENYL 1877755 11% 55% 147 Search DEPRENYL Search DEPRENYL
4 L DEPRENYL 1022456 5% 73% 60 Search L+DEPRENYL Search L+DEPRENYL
5 SAFINAMIDE 331306 2% 68% 21 Search SAFINAMIDE Search SAFINAMIDE
6 DEPRENYL SELEGILINE 179149 1% 77% 10 Search DEPRENYL+SELEGILINE Search DEPRENYL+SELEGILINE
7 DESMETHYLSELEGILINE 165616 1% 89% 8 Search DESMETHYLSELEGILINE Search DESMETHYLSELEGILINE
8 MAO B INHIBITION 145109 1% 69% 9 Search MAO+B+INHIBITION Search MAO+B+INHIBITION
9 ENHANCER SUBSTANCES 139740 0% 100% 6 Search ENHANCER+SUBSTANCES Search ENHANCER+SUBSTANCES
10 MAO B INHIBITOR 126953 1% 42% 13 Search MAO+B+INHIBITOR Search MAO+B+INHIBITOR

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref. in
cl.		 Shr. of ref. in
cl.		 Citations
1 FOLEY, P , GERLACH, M , YOUDIM, MBH , RIEDERER, P , (2000) MAO-B INHIBITORS: MULTIPLE ROLES IN THE THERAPY OF NEURODEGENERATIVE DISORDERS?.PARKINSONISM & RELATED DISORDERS. VOL. 6. ISSUE 1. P. 25 -47 117 58% 46
2 MAGYAR, K , SZENDE, B , JENEI, V , TABI, T , PALFI, M , SZOKO, E , (2010) R-DEPRENYL: PHARMACOLOGICAL SPECTRUM OF ITS ACTIVITY.NEUROCHEMICAL RESEARCH. VOL. 35. ISSUE 12. P. 1922 -1932 60 76% 12
3 MAGYAR, K , PALFI, M , TABI, T , KALASZ, H , SZENDE, B , SZOKO, E , (2004) PHARMACOLOGICAL ASPECTS OF (-)-DEPRENYL.CURRENT MEDICINAL CHEMISTRY. VOL. 11. ISSUE 15. P. 2017 -2031 71 72% 38
4 WEINREB, O , AMIT, T , BAR-AM, O , YOUDIM, MBH , (2010) RASAGILINE: A NOVEL ANTI-PARKINSONIAN MONOAMINE OXIDASE-B INHIBITOR WITH NEUROPROTECTIVE ACTIVITY.PROGRESS IN NEUROBIOLOGY. VOL. 92. ISSUE 3. P. 330-344 62 62% 69
5 WEINREB, O , AMIT, T , SAGI, Y , DRIGUES, N , YOUDIM, MBH , (2009) GENOMIC AND PROTEOMIC STUDY TO SURVEY THE MECHANISM OF ACTION OF THE ANTI-PARKINSON'S DISEASE DRUG, RASAGILINE COMPARED WITH SELEGILINE, IN THE RAT MIDBRAIN.JOURNAL OF NEURAL TRANSMISSION. VOL. 116. ISSUE 11. P. 1457 -1472 57 80% 12
6 CHEN, JJ , SWOPE, DM , (2005) CLINICAL PHARMACOLOGY OF RASAGILINE: A NOVEL, SECOND-GENERATION PROPARGYLAMINE FOR THE TREATMENT OF PARKINSON DISEASE.JOURNAL OF CLINICAL PHARMACOLOGY. VOL. 45. ISSUE 8. P. 878 -894 58 81% 68
7 WEINREB, O , AMIT, T , RIEDERER, P , YOUDIM, MBH , MANDEL, SA , (2011) NEUROPROTECTIVE PROFILE OF THE MULTITARGET DRUG RASAGILINE IN PARKINSON'S DISEASE.MONOAMINE OXIDASES AND THEIR INHIBITORS. VOL. 100. ISSUE . P. 127-149 66 62% 17
8 KALASZ, H , MAGYAR, K , SZOKE, E , ADEGHATE, E , ADEM, A , HASAN, MY , NURULAIN, SM , TEKES, K , (2014) METABOLISM OF SELEGILINE [(-)-DEPRENYL)].CURRENT MEDICINAL CHEMISTRY. VOL. 21. ISSUE 13. P. 1522-1530 54 73% 2
9 CHEN, JJ , LY, AV , (2006) RASAGILINE: A SECOND-GENERATION MONOAMINE OXIDASE TYPE-B INHIBITOR FOR THE TREATMENT OF PARKINSON'S DISEASE.AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY. VOL. 63. ISSUE 10. P. 915 -928 57 79% 30
10 FERNANDEZ, HH , CHEN, JJ , (2007) MONOAMINE OXIDASE-B INHIBITION IN THE TREATMENT OF PARKINSON'S DISEASE.PHARMACOTHERAPY. VOL. 27. ISSUE 12. P. 174S-185S 54 74% 64

Classes with closest relation at Level 1


Rank Class id link
1 4990 MONOAMINE OXIDASE//MAO B//MONOAMINE OXIDASE B
2 10431 MOCLOBEMIDE//ATYPICAL DEPRESSION//BROFAROMINE
3 29114 PRAMIPEXOLE//PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE//TALIPEXOLE
4 372 DYSKINESIA//LEVODOPA//MOTOR FLUCTUATIONS
5 3681 MPTP//MPP//1 METHYL 4 PHENYL 1 2 3 6 TETRAHYDROPYRIDINE
6 7381 NEUROMELANIN//AMINOCHROME//DOPAMINE QUINONE
7 14187 TRACE AMINES//BETA PHENYLETHYLAMINE//3 IODOTHYRONAMINE
8 13868 ENTACAPONE//TOLCAPONE//COMT INHIBITORS
9 15312 FENPROPOREX//AMPHETAMINE//DIMETHYLAMPHETAMINE
10 17570 SALSOLINOL//1 2 3 4 TETRAHYDROISOQUINOLINE//1 BENZYL 1 2 3 4 TETRAHYDROISOQUINOLINE

Go to start page